Top

Published in:

01-12-2021 | Cytostatic Therapy | Peritoneal Surface Malignancy

Ratio of Pathological Response to Preoperative Chemotherapy in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer Correlates with Survival

Authors: Eyal Mor, MD, Dan Assaf, MD, Shachar Laks, MD, Haggai Benvenisti, MD, Gal Schtrechman, MSc, David Hazzan, MD, Lior Segev, MD, Ronel Yaka, MD, Einat Shacham-Shmueli, MD, Ofer Margalit, MD, Naama Halpern, MD, Daria Perelson, MD, Monica-Inda Kaufmann, MD, Almog Ben-Yaacov, MD, Aviram Nissan, MD, Mohammad Adileh, MD

Published in: Annals of Surgical Oncology | Issue 13/2021

Abstract

Background

Pathological response of colorectal peritoneal metastasis (CRPM) may affect prognosis. We investigated the relationship between oncological outcomes and pathological response to chemotherapy of CRPM following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods

We conducted a retrospective analysis of a prospectively maintained Peritoneal Surface Malignancies database between 2015 and 2020. Analysis included patients with CRPM who underwent a CRS/HIPEC procedure (n = 178). The cohort was divided into three groups according to the response ratio (ratio of tumor-positive specimens to the total number of specimens resected): Group A, complete response; Group B, high response ratio, and Group C, low response ratio.

Results

The group demographics were similar, but the overall complication rate was higher in Group C (65.2%) compared with Groups A (55%) and B (42.8%) [p = 0.03]. Survival correlated to response ratio; the estimated median disease-free survival of Group C was 9.1 months (5.97–12.23), 14.9 months (4.72–25.08) for Group B, and was not reached in Group A (p = 0.001). The estimated median overall survival in Group C was 35 months (26.69–43.31), and was not reached in Groups A and B (p = 0.001).

Conclusions

The pathological response ratio to systemic therapy correlates with survival in patients undergoing CRS/HIPEC. This study supports the utilization of preoperative therapy for better patient selection, with a potential impact on survival.

Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6(1):29765. https://doi.org/10.1038/srep29765.CrossRefPubMedPubMedCentral

Holch JW, Demmer M, Lamersdorf C, et al. Pattern and dynamics of distant metastases in metastatic colorectal cancer. Visc Med. 2017;33(1):70–5. https://doi.org/10.1159/000454687.CrossRefPubMedPubMedCentral

Arakawa K, Kawai K, Ishihara S, et al. Prognostic significance of peritoneal metastasis in stage IV colorectal cancer patients with R0 resection. Dis Colon Rectum. 2017;60(10):1041–9. https://doi.org/10.1097/DCR.0000000000000858.CrossRefPubMed

Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–50. https://doi.org/10.1046/j.1365-2168.2002.02274.x.CrossRefPubMed

Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. https://doi.org/10.1002/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o.CrossRefPubMed

Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26(35):5721–7. https://doi.org/10.1200/JCO.2008.17.7147.CrossRefPubMedPubMedCentral

Renouf DJ, Lim HJ, Speers C, et al. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer. 2011;10(2):97–101. https://doi.org/10.1016/j.clcc.2011.03.004.CrossRefPubMed

Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis. JAMA Oncol. 2015;1(6):787–95. https://doi.org/10.1001/jamaoncol.2015.1790.CrossRefPubMed

Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14(3):254–61. https://doi.org/10.1002/(sici)1098-2388(199804/05)14:3%3c254::aid-ssu10%3e3.0.co;2-u.CrossRefPubMed

10.

Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92. https://doi.org/10.1200/JCO.2004.10.012.CrossRefPubMed

11.

Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. https://doi.org/10.1200/JCO.2003.04.187.CrossRefPubMed

12.

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.CrossRefPubMed

13.

Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5. https://doi.org/10.1200/JCO.2008.19.7160.CrossRefPubMed

14.

Di Miceli D, Alfieri S, Caprino P, et al. Complications related to hyperthermia during hypertermic intraoperative intraperitoneal chemiotherapy (HIPEC) treatment Do they exist? Eur Rev Med Pharmacol Sci. 2012;16(6):737–42.PubMed

15.

Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI. Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2017;24(4):890–7. https://doi.org/10.1245/s10434-016-5738-6.CrossRefPubMed

16.

Faron M, Macovei R, Goéré D, Honoré C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23(1):114–9. https://doi.org/10.1245/s10434-015-4627-8.CrossRefPubMed

17.

Tentes A-AK, Tripsiannis G, Markakidis SK, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29(1):69–73. https://doi.org/10.1053/ejso.2002.1380.CrossRefPubMed

18.

Bhatt A, Yonemura Y, Mehta S, et al. The Pathologic Peritoneal Cancer Index (PCI) strongly differs from the surgical PCI in peritoneal metastases arising from various primary tumors. Ann Surg Oncol. 2020;27(8):2985–96. https://doi.org/10.1245/s10434-020-08234-x.CrossRefPubMed

19.

Berger Y, Jacoby H, Kaufmann MI, et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26(4):1103–9. https://doi.org/10.1245/s10434-019-07219-9.CrossRefPubMed

20.

Goéré D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958–64. https://doi.org/10.1245/s10434-015-4387-5.CrossRefPubMed

21.

Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA, Heriot AG. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016;18(3):234–46. https://doi.org/10.1111/codi.13207.CrossRefPubMed

22.

Polanco PM, Mokdad AA, Zhu H, Choti MA, Huerta S. Association of adjuvant chemotherapy with overall survival in patients with rectal cancer and pathologic complete response following neoadjuvant chemotherapy and resection. JAMA Oncol. 2018;4(7):938–43. https://doi.org/10.1001/jamaoncol.2018.0231.CrossRefPubMedPubMedCentral

23.

Blazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51. https://doi.org/10.1200/JCO.2008.17.5299.CrossRefPubMed

24.

Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.CrossRef

25.

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23.CrossRefPubMed

26.

Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications. Ann Surg. 2009;250(2):187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2.CrossRefPubMed

27.

Dede K, Salamon F, Landherr L, Jakab F, Bursics A. Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use? Pathol Oncol Res. 2015;21(1):173–9. https://doi.org/10.1007/s12253-014-9803-9.CrossRefPubMed

28.

Chan G, Hassanain M, Chaudhury P, et al. Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. HPB (Oxford). 2010;12(4):277–84. https://doi.org/10.1111/j.1477-2574.2010.00170.x.CrossRefPubMedPubMedCentral

29.

Karagkounis G, Thai L, Mace AG, et al. Prognostic implications of pathological response to neoadjuvant chemoradiation in pathologic stage III rectal cancer. Ann Surg. 2019;269(6):1117–23. https://doi.org/10.1097/SLA.0000000000002719.CrossRefPubMed

30.

Hoendervangers S, Burbach JPM, Lacle MM, et al. Pathological complete response following different neoadjuvant treatment strategies for locally advanced rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2020;27(11):4319–36. https://doi.org/10.1245/s10434-020-08615-2.CrossRefPubMedPubMedCentral

31.

Spiliotis J, Kalles V, Kyriazanos I, et al. CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: the small-bowel PCI score as a predictor of survival. Pleura Peritoneum. 2019;4(4):20190018. https://doi.org/10.1515/pp-2019-0018.CrossRefPubMedPubMedCentral

32.

Huang Y, Alzahrani NA, Chua TC, Liauw W, Morris DL. Impacts of peritoneal cancer index on the survival outcomes of patients with colorectal peritoneal carcinomatosis. Int J Surg. 2016;32:65–70. https://doi.org/10.1016/j.ijsu.2016.06.033.CrossRefPubMed

33.

Burnett A, Lecompte M-EA, Trabulsi N, et al. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. World J Surg Oncol. 2019;17(1):83. https://doi.org/10.1186/s12957-019-1618-4.CrossRefPubMedPubMedCentral

34.

Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: A new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608–14. https://doi.org/10.1245/s10434-014-3647-0.CrossRefPubMed

35.

Enblad M, Birgisson H, Wanders A, Sköldberg F, Ghanipour L, Graf W. Importance of absent neoplastic epithelium in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(4):1149–56. https://doi.org/10.1245/s10434-015-4989-y.CrossRefPubMed

Title: Ratio of Pathological Response to Preoperative Chemotherapy in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer Correlates with Survival
Authors: Eyal Mor, MD
Dan Assaf, MD
Shachar Laks, MD
Haggai Benvenisti, MD
Gal Schtrechman, MSc
David Hazzan, MD
Lior Segev, MD
Ronel Yaka, MD
Einat Shacham-Shmueli, MD
Ofer Margalit, MD
Naama Halpern, MD
Daria Perelson, MD
Monica-Inda Kaufmann, MD
Almog Ben-Yaacov, MD
Aviram Nissan, MD
Mohammad Adileh, MD
Publication date: 01-12-2021
Publisher: Springer International Publishing
Keyword: Cytostatic Therapy
Published in: Annals of Surgical Oncology / Issue 13/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-021-10367-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ratio of Pathological Response to Preoperative Chemotherapy in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer Correlates with Survival

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2021

Why Breast-Conserving Therapy Should be Considered Treatment of Choice in Early-Stage Breast Cancer Patients

ASO Author Reflections: Comparison of Three Lymph Node Staging Systems for Prognostic Evaluation of Resected Gastric Adenocarcinoma

ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?

Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma

Complete Mesocolic Excision and D3 Lymphadenectomy versus Conventional Colectomy for Colon Cancer: A Systematic Review and Meta-Analysis

Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19